[go: up one dir, main page]

BR0010354A - Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção - Google Patents

Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção

Info

Publication number
BR0010354A
BR0010354A BR0010354-3A BR0010354A BR0010354A BR 0010354 A BR0010354 A BR 0010354A BR 0010354 A BR0010354 A BR 0010354A BR 0010354 A BR0010354 A BR 0010354A
Authority
BR
Brazil
Prior art keywords
lipid
liquid
particles
solid
production
Prior art date
Application number
BR0010354-3A
Other languages
English (en)
Inventor
Rainer Helmut Mueller
Volkhard Jenning
Karsten Maeder
Andreas Lippacher
Original Assignee
Pharmasol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999138371 external-priority patent/DE19938371A1/de
Priority claimed from DE19945203A external-priority patent/DE19945203A1/de
Application filed by Pharmasol Gmbh filed Critical Pharmasol Gmbh
Publication of BR0010354A publication Critical patent/BR0010354A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Cosmetics (AREA)

Abstract

Patente de Invenção: "PARTìCULAS DE LIPìDEO à BASE EM MISTURAS DE LIPìDEOS LìQUIDOS E SóLIDOS E MéTODO PARA A SUA PRODUçãO". A invenção refere-se a partículas de lipídeo sem droga e carregadas com droga de uma matriz mista feita de lipídeos sólidos e líquidos, e a um método para a produção de dispersões de partícula de lipídeo altamente concentradas de partículas sólidas-líquidas tendo um teor de lipídeo de a partir de 30% a 95% ou um teor de sólidos de a partir de 30% a 95% (lipídeo e estabilizador), que em contraste com os creme bianfifílicos são partículas inteiras, e/ou que quando da diluição das dispersões de partícula altamente concentradas com a fase externa resultam em dispersões de partícula de fluxo livre.
BR0010354-3A 1999-05-07 2000-05-08 Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção BR0010354A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19921034 1999-05-07
DE1999138371 DE19938371A1 (de) 1999-08-09 1999-08-09 Zusammensetzung, Herstellung und Verwendung einer Suspension verfestigter, amorpher Öltröpfchen
DE19945203A DE19945203A1 (de) 1999-05-07 1999-09-21 Fest-flüssig (halbfeste) Lipidpartikel (Nano-Compartiment-Carrier-NCC) und Verfahren zur Herstellung hochkonzentrierter Lipidpartikel
DE10016357 2000-03-31
PCT/EP2000/004112 WO2000067728A2 (de) 1999-05-07 2000-05-08 Lipidpartikel auf der basis von mischungen von flüssigen und festen lipiden und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
BR0010354A true BR0010354A (pt) 2002-03-05

Family

ID=27437798

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010354-3A BR0010354A (pt) 1999-05-07 2000-05-08 Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção

Country Status (8)

Country Link
EP (1) EP1176949B1 (pt)
JP (1) JP2002544155A (pt)
AU (1) AU4917900A (pt)
BR (1) BR0010354A (pt)
CA (1) CA2369594A1 (pt)
MX (1) MXPA01011343A (pt)
TR (1) TR200103188T2 (pt)
WO (1) WO2000067728A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101070A2 (hu) 1998-03-12 2001-07-30 The Procter & Gamble Co. Enziminhibitort tartalmazó bőrápoló készítménnyel ellátott eldobható abszorbens cikkek
CA2375556A1 (en) * 1999-07-13 2001-01-18 Pharmasol Gmbh Uv radiation reflecting or absorbing agents, protecting against harmful uv radiation and reinforcing the natural skin barrier
WO2001043717A1 (en) * 1999-12-17 2001-06-21 The Procter & Gamble Company Compositions for efficient release of active ingredients
NZ504526A (en) * 2000-05-12 2003-05-30 Meracol Corp Ltd Treating herpes simplex symptoms using a mixture of cetyl myristate and cetyl palmitate
US20030153620A1 (en) 2000-05-12 2003-08-14 Meakin Timothy David Treating eczema and/or psoriasis
WO2001085162A1 (en) * 2000-05-12 2001-11-15 Meracol Corporation Limited Treating irritable bowel syndrome or disease
DE60132008T2 (de) * 2000-05-12 2008-12-11 Meracol Corp. Ltd., Takapuna Cetylmyristat und cetylpalmitat zur behandlung von ekzemen und/oder psoriasis
DE10065217A1 (de) * 2000-12-27 2002-07-18 Pharmasol Gmbh Transfektionskomplexe (TransoPlex) mit reduzierter Toxizität, hoher physikalischer Stabilität und hoher Transfektionseffizienz sowie Verfahren zu ihrer Herstellung
DE10228680A1 (de) * 2002-06-27 2004-01-22 Holden Development Limited, Tortola Grundlage für transdermale Formulierungen (PTF)
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
FR2852843B1 (fr) 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
CA2524589A1 (en) * 2003-05-07 2004-11-18 Ifac Gmbh & Co. Kg Compositions for the targetted release of fragrances and aromas
EP1660033B1 (de) 2003-08-27 2010-11-10 Beiersdorf AG Kosmetische kugelförmige zubereitungen zur topischen anwendung
JP2007503418A (ja) 2003-08-27 2007-02-22 バイヤースドルフ・アクチエンゲゼルシヤフト 局所使用中に個別には感知不能になる外皮を有するカプセル
DE10357639A1 (de) 2003-08-27 2005-03-24 Beiersdorf Ag Kosmetische und/oder dermatologische Kapsel
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
US9114077B2 (en) 2006-11-17 2015-08-25 Abbvie Deutschland Gmbh & Co Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
DE102007055341A1 (de) 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
EP2441441A1 (en) * 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi A sieving method for cetyl myristate and/or cetyl palmitate
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
GB201021937D0 (en) * 2010-12-24 2011-02-02 Reckitt & Colman Overseas Skin sanitizer compositions comprising alcohol based emulsion
JP5940556B2 (ja) 2010-12-28 2016-06-29 ユニリーバー・ナームローゼ・ベンノートシヤープ エマルジョンの製造方法
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR20140031227A (ko) * 2011-03-24 2014-03-12 레오 파마 에이/에스 지질 나노입자들 및 코르티코스테로이드 또는 비타민 ｄ 유도체를 포함하는 조성물
EP2760433B1 (en) * 2011-09-29 2023-05-31 PLx Opco Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
CN102688152A (zh) * 2012-06-05 2012-09-26 东南大学 复合防晒剂纳米结构脂质载体及其制备方法
EP2943223B1 (en) * 2013-01-14 2020-08-19 InFirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
RU2677346C2 (ru) * 2013-01-14 2019-01-16 ИнФерст Хэлткэр Лимитед Композиции и способы для лечения сильной боли
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
DE102013224627A1 (de) 2013-11-29 2015-06-03 Andreas Lauterbach Pharmazeutische Formulierung mit Lipidmikropartikeln und Herstellungsverfahren
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2017054071A1 (en) * 2015-01-21 2017-04-06 Willinsky Michael Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaler
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
EP3228359A1 (en) * 2016-04-06 2017-10-11 Infinitec Activos, S.L. Chlorella compositions and use therof for reducing dark circles under the eyes
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
SG11201908457WA (en) 2017-03-15 2019-10-30 Cerecin Inc Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
AU2019236238B2 (en) * 2018-03-15 2024-12-19 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
KR102037354B1 (ko) * 2018-12-07 2019-10-28 (주) 바이노텍 생리활성물질 봉입을 위한 나노지질전달체 및 이의 제조방법
EP4125820A4 (en) 2020-03-26 2024-04-10 PLx Opco Inc. Pharmaceutical carriers capable of ph dependent reconstitution and methods for making and using same
DE102023103292A1 (de) * 2023-02-10 2024-08-14 Cineolux Gmbh Dispersion und Zubereitung zur topischen Anwendung
CN116406663A (zh) * 2023-04-11 2023-07-11 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种含草蒿脑的果蝇驱避剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
DK0525307T3 (da) * 1991-07-23 1996-04-01 American Cyanamid Co Stabile præparater til parenteral indgivelse og deres anvendelse
US5250236A (en) * 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
EP0671937A4 (en) * 1992-10-16 1996-09-18 Smithkline Beecham Corp COMPOSITIONS FOR PHARMACEUTICAL EMULSIONS.
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
JP3454385B2 (ja) * 1993-10-15 2003-10-06 啓次郎 佐藤 Ｏ／ｗ型皮膚用クリームの製造方法
US6333021B1 (en) * 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
JPH09151112A (ja) * 1995-11-30 1997-06-10 Noevir Co Ltd 微細エマルション組成物
FR2775441B1 (fr) * 1998-02-27 2000-04-28 Serobiologiques Lab Sa Matrice pour la preparation de microparticules ou de nanoparticules, procede de fabrication de telles particules et particules obtenues

Also Published As

Publication number Publication date
EP1176949B1 (de) 2014-12-10
MXPA01011343A (es) 2002-06-04
JP2002544155A (ja) 2002-12-24
AU4917900A (en) 2000-11-21
TR200103188T2 (tr) 2002-04-22
CA2369594A1 (en) 2000-11-16
WO2000067728A2 (de) 2000-11-16
WO2000067728A3 (de) 2001-08-09
EP1176949A2 (de) 2002-02-06

Similar Documents

Publication Publication Date Title
BR0010354A (pt) Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção
US5885974A (en) Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
Holt et al. Properdin binds to sulfatide [Gal (3-SO4) beta 1-1 Cer] and has a sequence homology with other proteins that bind sulfated glycoconjugates.
Hąc-Wydro et al. The study on the interaction between phytosterols and phospholipids in model membranes
Alvarez-Sala et al. Impact of lipid components and emulsifiers on plant sterols bioaccessibility from milk-based fruit beverages
ATE533534T1 (de) Proteinhydrolysat und pflanzliche sterole enthaltende zusammensetzung für verbessern serum- lipid-profils und das verhindern von atherosclerosis
BR0208207A (pt) Redução da imunogenicidade das proteìnas de fusão
BR0113621A (pt) Esteróis encapsulados que podem ser dispersados em água
BR9815302A (pt) Método para diminuir a concentração de colesterol ldl e aumentar a concentração de colesterol hdl no sangue para reduzir o risco de aterosclerose e doença vascular
BR0011234A (pt) Composições de glicomanana e métodos para reduzir a viscosidade de composições de glicomanana
BR9609012A (pt) "novos nor-pregnanos para indução de efeitos hipolalâmicos"
Fowler et al. Substrate-selective activation of rat liver mitochondrial mono amine oxidase by oxygen
BR9915770A (pt) Tarugo de expansão
BR9307719A (pt) Atovaquona na forma de partìculas, partìculas microfluidizadas de atovaquona, composição farmacêutica, e métodos para a preparação de partìculas microfluidizadas de atovaquona e para a preparaçào de composições farmacêuticas
BR9807772A (pt) Flange solto de segurança de duas partes
BR9815492A (pt) Composição cosmética e dermatológica à base de partìculas magnéticas duras
Brito et al. Assessment of bilirubin toxicity to erythrocytes. Implication in neonatal jaundice management
BR0109802A (pt) Preparações farmacêuticas e sua fabricação
Donovan et al. Molecular species composition of inter-mixed micellar/vesicular bile salt concentrations in model bile: dependence upon hydrophilic-hydrophobic balance
BRPI0309421A8 (pt) Método de preparar um gênero alimentício e composição para tratar ou prevenir hipercolesterolemia
BR9916821A (pt) Ligantes de receptor nuclear
Mouécoucou et al. Effects of gum arabic, low methoxy pectin and xylan on in vitro digestibility of peanut protein
DE50211883D1 (de) Verwendung von Wirkstoffmischungen mit Azelainsäure und Glycyrrhetinsäure als Anti-Aknemittel
Motoyama et al. Effect of 2, 6-di-O-methyl-α-cyclodextrin on hemolysis and morphological change in rabbit's red blood cells
CA2236641A1 (en) Preparation of fagopyritols and uses therefor

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO DA RPI 1962 DE 12/08/2008.